Physician profile
John Roesler
NPI 1124037635
$5,694.51
in general payments reported to CMS, 2019-2025
24 companies · $463 in 2025
The $463 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $598 · 2021: $930 · 2022: $505 · 2023: $999 · 2024: $1,115 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.76 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,996.70 | 2019-2024 | Xeomin |
| Abbvie INC. | $1,000.62 | 2023-2025 | Botox |
| Galderma Laboratories, L.P. | $852.47 | 2019-2025 | |
| Allergan, INC. | $564.01 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $186.84 | 2019-2025 | |
| Revance Therapeutics, INC. | $185.60 | 2024-2025 | Daxxify |
| Optinose US, INC. | $162.70 | 2019-2024 | |
| Inspire Medical Systems, INC. | $131.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $101.50 | 2020-2024 | Dupixent |
| Almirall LLC | $99.94 | 2023-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $73.14 | 2019-2023 | Adbry |
| Janssen Biotech, INC. | $41.15 | 2022-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $39.75 | 2021-2024 | |
| Medtronic, INC. | $37.88 | 2023 | Sinuva |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $36.01 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $31.91 | 2019-2020 | |
| Journey Medical Corporation | $24.70 | 2023 | |
| Stryker Corporation | $21.63 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.60 | 2019 | |
| Biofrontera INC. | $20.50 | 2019 | |
| Organogenesis INC. | $19.10 | 2024 | |
| Medimetriks Pharmaceuticals, INC. | $16.09 | 2025 | Genadur, Clindacin Etz |
| Genzyme Corporation | $15.55 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $13.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Roesler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.